ENDECE Neural announced plans to attend the 34th annual J.P. Morgan Healthcare Conference from January 11-14, 2016 at the Westin St. Francis Hotel in San Francisco, Calif. The industry’s largest healthcare investment symposium, the J.P. Morgan Healthcare Conference provided a highly visible forum for ENDECE Neural to discuss the company’s efforts to develop therapies that repair the damage caused by devastating neurological diseases such as multiple sclerosis (MS).
ENDECE Neural’s lead compound, NDC-1308, is a novel chemical entity designed to address one of the root causes of MS symptoms: the demyelination of nerves in the brain and spinal cord. NDC-1308 triggers the processes of oligodendrogenesis to ultimately restore the myelin sheath that is damaged in patients with MS. NDC-1308 is a small molecule that readily crosses the blood-brain barrier, allowing it to reach the tissues in the brain and spinal cord where promoting myelin production is needed. Its unique mechanism of action may enable its use either alone or in combination with other MS therapeutics that slow the progression of the disease. NDC-1308 is in late-stage preclinical development and ENDECE Neural is seeking a commercial partner to complete clinical trials and bring the therapy to market.
If you are attending the J.P. Morgan Healthcare Conference and would like to meet with ENDECE Neural to discuss the latest developments with NDC-1308, please contact Jean Yarger at